Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin

Sareena Khosla, Jacqueline Crawley

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A new antagonist of the peripheral cholecystokinin receptor, L-364,718, was found to block the reductions in food intake and exploratory activity induced by intraperitoneal administration of cholecystokinin octapeptide sulfate. L-364,718 significantly reversed the cholecystokinin-induced reduction in feeding at doses of 10 μg/kg - 10 mg/kg i.p. L-364,718 significantly reversed the cholecystokinin-induced reduction in exploratory activity at doses of 500 ng/kg - 10 mg/kg i.p. The time course of antagonist activity of L-364,718 was immediate to 90 minutes after intraperitoneal administration. L-364,718 had no significant effect on food intake or exploratory activity when administered alone, over the dose range of 100 ng/kg-10 mg/kg i.p. This compound appears to be at least one hundred times more potent than proglumide or benzotript as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalLife Sciences
Volume42
Issue number2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Devazepide
Cholecystokinin
Proglumide
Cholecystokinin Receptors
Sincalide
Eating
Sulfates

ASJC Scopus subject areas

  • Pharmacology

Cite this

Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin. / Khosla, Sareena; Crawley, Jacqueline.

In: Life Sciences, Vol. 42, No. 2, 1988, p. 153-159.

Research output: Contribution to journalArticle

@article{c9d5a9fdc3df49dda68b9f7d66d214ba,
title = "Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin",
abstract = "A new antagonist of the peripheral cholecystokinin receptor, L-364,718, was found to block the reductions in food intake and exploratory activity induced by intraperitoneal administration of cholecystokinin octapeptide sulfate. L-364,718 significantly reversed the cholecystokinin-induced reduction in feeding at doses of 10 μg/kg - 10 mg/kg i.p. L-364,718 significantly reversed the cholecystokinin-induced reduction in exploratory activity at doses of 500 ng/kg - 10 mg/kg i.p. The time course of antagonist activity of L-364,718 was immediate to 90 minutes after intraperitoneal administration. L-364,718 had no significant effect on food intake or exploratory activity when administered alone, over the dose range of 100 ng/kg-10 mg/kg i.p. This compound appears to be at least one hundred times more potent than proglumide or benzotript as an antagonist of the behavioral effects of peripherally administered cholecystokinin.",
author = "Sareena Khosla and Jacqueline Crawley",
year = "1988",
doi = "10.1016/0024-3205(88)90678-9",
language = "English (US)",
volume = "42",
pages = "153--159",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin

AU - Khosla, Sareena

AU - Crawley, Jacqueline

PY - 1988

Y1 - 1988

N2 - A new antagonist of the peripheral cholecystokinin receptor, L-364,718, was found to block the reductions in food intake and exploratory activity induced by intraperitoneal administration of cholecystokinin octapeptide sulfate. L-364,718 significantly reversed the cholecystokinin-induced reduction in feeding at doses of 10 μg/kg - 10 mg/kg i.p. L-364,718 significantly reversed the cholecystokinin-induced reduction in exploratory activity at doses of 500 ng/kg - 10 mg/kg i.p. The time course of antagonist activity of L-364,718 was immediate to 90 minutes after intraperitoneal administration. L-364,718 had no significant effect on food intake or exploratory activity when administered alone, over the dose range of 100 ng/kg-10 mg/kg i.p. This compound appears to be at least one hundred times more potent than proglumide or benzotript as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

AB - A new antagonist of the peripheral cholecystokinin receptor, L-364,718, was found to block the reductions in food intake and exploratory activity induced by intraperitoneal administration of cholecystokinin octapeptide sulfate. L-364,718 significantly reversed the cholecystokinin-induced reduction in feeding at doses of 10 μg/kg - 10 mg/kg i.p. L-364,718 significantly reversed the cholecystokinin-induced reduction in exploratory activity at doses of 500 ng/kg - 10 mg/kg i.p. The time course of antagonist activity of L-364,718 was immediate to 90 minutes after intraperitoneal administration. L-364,718 had no significant effect on food intake or exploratory activity when administered alone, over the dose range of 100 ng/kg-10 mg/kg i.p. This compound appears to be at least one hundred times more potent than proglumide or benzotript as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

UR - http://www.scopus.com/inward/record.url?scp=0023704921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023704921&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(88)90678-9

DO - 10.1016/0024-3205(88)90678-9

M3 - Article

VL - 42

SP - 153

EP - 159

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 2

ER -